AstraZeneca (AZN) Tops Q4 EPS by 71c; initiates guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
- Shipping stocks on fire — but cracks are forming in the rate rally
AstraZeneca's earnings top estimates but shares fall on core operating profit drop
February 8, 2024 6:41 AM ESTAstraZeneca (NASDAQ: AZN) shares fell more than 6% in premarket trading Thursday after the drugmaker reported notably lower-than-expected core operating profit for the fourth quarter.
Earnings per share (EPS) came in at $1.45 in Q4, topping the forecasted $0.74. The pharmaceutical giant generated a quarterly revenue of $12.02 billion, also above the consensus estimate of $12 billion.
Core operating profit rose 5.4% year-over-year to $2.75 billion, but was... More
Deutsche Bank Downgrades AstraZeneca (AZN) to Hold
February 8, 2024 5:37 AM ESTDeutsche Bank analyst Emmanuel Papadakis downgraded AstraZeneca (NASDAQ: AZN) from Buy to Hold.
The analyst comments "Q4 is a thoroughly underwhelming end to 2023 with a soft print that missed in most of the places that matter (Enhertu included, again), whilst FY24 guidance is... More
